Revisión sistemática
No clasificado
Sin referencias
Alpha-glucosidase inhibitors (AGIs) was reported to be associated with several rare adverse hepatic events, but with inconsistent results. We aimed to investigate the risk of hepatotoxicity associated with the use of AGIs in patients with type 2 diabetes mellitus (T2DM), and performed a systematic review and meta-analysis. Fourteen studies (n = 2881) were eligible, all of which were RCTs. Meta-analysis of data regarding elevation of more than 3-fold the upper limit of normal (ULN) of AST and ALT showed statistically significant differences between AGIs treatment versus control (OR 6.86, 95% CI 2.50 to 18.80; OR 6.48, 95% CI 2.40 to 17.49). Subgroup analyses of elevation of more than 1.8-fold ULN of AST and ALT by dose of AGIs showed differential effects on AST and ALT (
Síntesis amplia
No clasificado
Este artículo incluye 30 Estudios primarios Estudios primarios (30 referencias) 2 Revisiones sistemáticas Revisiones sistemáticas (2 referencias)
Revisión sistemática
No clasificado
Sin referencias
We very much appreciate the editors' invitation to comment on the systematic review and meta-analysis by Maybury and colleagues, which examined the risk of histologically-confirmed liver fibrosis attributable to methotrexate (MTX) among patients with psoriasis.The authors identified eight studies, all over a decade old, and based on the subset utilising pre- and post-MTX biopsies reported that methotrexate increases the risk of both any liver fibrosis and cirrhosis; that the risk was not increased when studies utilising either serial biopsies or "significant fibrosis" as an endpoint were assessed; and that the role of potential confounders such as obesity and diabetes remains unclear. Although the authors have clearly invested considerable effort in conducting this study, several shortcomings are noteworthy. This article is protected by copyright. All rights reserved.
Resumen estructurado de revisiones sistemáticas
No clasificado
Este artículo incluye 1 Revisión sistemática Revisiones sistemáticas (1 referencia)
Este artículo no tiene resumen
Estudio primario
No clasificado
Este artículo está incluido en 1 Revisión sistemática Revisiones sistemáticas (1 referencia)
Este artículo no tiene resumen
Estudio primario
No clasificado
Este artículo está incluido en 1 Revisión sistemática Revisiones sistemáticas (1 referencia)
Este artículo no tiene resumen
Estudio primario
No clasificado
Este artículo está incluido en 1 Revisión sistemática Revisiones sistemáticas (1 referencia)
Este artículo no tiene resumen
Estudio primario
No clasificado
Este artículo está incluido en 2 Revisiones sistemáticas Revisiones sistemáticas (2 referencias)
Pyrazinamide (PZA) combined with either ethambutol (EMB) or a fluoroquinolone for 6-12 months is one of the treatments recommended for latent tuberculosis infection (LTBI) in contacts exposed to multidrug-resistant tuberculosis (MDR-TB). The aim of the present study was to describe the side effects related to combined PZA and EMB treatment given for LTBI, in contacts previously exposed to MDR-TB. In total, 12 consecutive contacts, all of African origin and aged 38+/-5 yrs, were treated with daily PZA (23+/-4 mg.kg(-1)) and EMB (17+/-4 mg.kg(-1)) at Geneva University Hospital outpatient clinic (Switzerland), as a result of contact-tracing procedures for two patients with contagious MDR-TB. Clinical status and liver function tests (aspartate aminotransferase (ALAT) and alanine aminotransferase (ASAT)) were monitored monthly. In seven cases (58%) treatment was discontinued after a median of 119 days, due to hepatic toxicity in six cases (ALAT or ASAT elevation more than four times the upper normal limit), and gastrointestinal symptoms in one case. In conclusion, combined pyrazinamide and ethambutol for latent tuberculosis infection may be associated with a high risk of hepatic toxicity, and warrants close monitoring. There is clearly a need for alternative preventive treatments for contacts exposed to multidrug-resistant tuberculosis.
Revisión sistemática
No clasificado
Sin referencias
Este artículo está incluido en 1 Resumen estructurado de revisiones sistemáticas 0 Resúmenes estructurados de revisiones sistemáticas (1 referencia)
Drug-induced hepatotoxicity is the leading cause of acute liver failure (ALF) in the US and the most common adverse event causing drug non-approval and drug withdrawal by the U.S. Food and Drug Administration (FDA). Three different nonsteroidal anti-inflammatory drugs (NSAIDs) have been withdrawn in the UK and/or the US due to hepatotoxicity (bromfenac, ibufenac, and benoxaprofen). A systematic review of clinical trials data for these drugs was performed in an effort to identify possible early signals that could have predicted post-marketing serious hepatoxicity. There were very limited published data on benoxaprofen and none on ibufenac or bromfenac. The publicly accessible archives of the FDA provided information on bromfenac. Flu-like symptoms associated with hepatic enzyme elevation and a case of possible drug-related hepatocellular jaundice may in retrospect have been signals for serious hepatotoxicity in the database of 1195 subjects reviewed by the FDA. Following approval, rates of acute liver failure for bromfenac were estimated to be in the range of 1:10 000. In addition, the safety databases of several drugs also accessed through FDA archives have been reviewed (simvastatin, tacrine, troglitazone, and ximelagatran). These data suggest that while ALT elevations alone do not reliably signal serious hepatotoxicity, elevated transaminases in association with symptomatic hepatitis or jaundice may be predictors of an increased risk of ALF. At present, however, pre-approval databases are generally not large enough to rule out low rates of serious hepatotoxicity. Therefore, it remains critical that clinicians report such cases to the FDA through the MEDWATCH system and that active post-marketing monitoring studies be used to identify potential rare cases of hepatotoxicity.
Revisión sistemática
No clasificado
Sin referencias
Este artículo está incluido en 1 Resumen estructurado de revisiones sistemáticas 0 Resúmenes estructurados de revisiones sistemáticas (1 referencia) 1 Síntesis amplia 0 Síntesis amplias (1 referencia)
Términos y Condiciones